Novavax has secured a transformative partnership with Sanofi, which includes $1.2 billion in potential payments and critical commercial support. The company’s COVID-19 vaccine targets the JN.
Per the deal terms, Sanofi took a minority stake in NVAX (a $70 million equity investment), will gain rights to co-market Novavax’s COVID-19 vaccine globally, and will have the sole license to ...
Sanofi, RadioMedix and Orano Med have entered into an exclusive licensing agreement worth €320m to develop a next-generation ...
Though Novavax is behind in the COVID-19 vaccine race, a blockbuster deal with Sanofi and a differentiated product means the stock offers the best reward prospects in the industry. Novavax stock ...
Per the deal terms, Sanofi took a minority stake in NVAX (a $70 million equity investment), will gain rights to co-market Novavax’s COVID-19 vaccine globally, and will have the sole license to develop ...
1:23 Most provinces have destroyed COVID-19 vaccines amid wait for new formula, here’s why Health Canada has authorized Novavax’s updated COVID-19 vaccine that protects against currently ...
Health Canada said Thursday it has authorized Novavax's updated COVID-19 vaccine for those aged 12 years and up. The product, called Nuvaxovid, is a protein-based vaccine. Health Canada said ...
Health Canada authorized Novavax’s updated COVID-19 vaccine that protects against currently circulating variants of the virus on Thursday. The protein-based vaccine, called Nuvaxovid ...